Sponsored by Novartis Jamie Lynn Sigler opens up about self-advocacy, finding her treatment plan and why your voice should be the loudest in the room when it comes to your health.

Binary Defense ARC Labs hosts ThreatTalk Ep. 11 on June 18: how AI is accelerating both cyberattacks and SOC defense. Live webinar, demo and Q&A.

Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today highlighted the role of its Scientific Advisory Board ...

Model Context Protocol (MCP) has gained considerable momentum as a standard connector between LLM-powered tools and local systems, internal and external APIs, and data sources. From major clouds to ...

Most research papers assume a human will read them first. However, Google DeepMind's latest sprawling 60-page look at the road from AGI to superintelligence doesn't bother with that pretense. Section ...

AI is changing the security landscape. More and more threat groups incorporate LLMs into their reconnaissance and exploitation workflows. The notion that some vulnerabilities are too complex to ...

Researchers have discovered two vulnerabilities in the widely used Cursor AI-enabled integrated development environment (IDE) ...

Pope Leo XIV states AI embeds ethical choices in its design, measurements, and classifications. Insights on dignity and ...

There is a lack of evidence to suggest the majority of in vitro fertilization (IVF) add-ons improve fertility in patients ...

Yes Bank touched a new 52-week high of ₹25.46 as investors cheered RBI's liquidity-supportive measures, attractive FCNR(B) deposit rates, and the bank's ongoing turnaround story. Backed by strong ...

Both models trade word-by-word generation for parallel denoising. Only one of them does it without losing intelligence in the ...

AbbVie today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody, and lenalidomide, compared to rituximab ...